CervoMed Analyst Ratings
Jones Trading Initiates Coverage On CervoMed With Buy Rating, Announces Price Target of $70
CervOmed Inc.: Jonestrading launches report with a buy rating; target price is $70
CervoMed's Buy Rating Backed by First-Mover Advantage in DLB Treatment and Positive Trial Prospects
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)
Canadian Investment Banking Group: Maintaining the CervOmed (CRVO.US) rating, adjusted from buy to buy rating, and adjusted the target price from $50.00 to $65.00.
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
CervoMed Analyst Ratings
Canaccord Genuity Initiates Coverage On CervoMed With Buy Rating, Announces Price Target of $50
CervoMed Analyst Ratings
Canaccord Initiates CervoMed With Buy, Says Stock Heavily Undervalued
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and CervoMed (CRVO)
No Data